You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Singapore Patent: 11201708602X


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Singapore Patent: 11201708602X

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Mar 7, 2037 Arrowhead REDEMPLO plozasiran sodium
⤷  Start Trial Mar 7, 2037 Arrowhead REDEMPLO plozasiran sodium
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent SG11201708602X: Scope, Claims, and Landscape Analysis

Last updated: February 26, 2026

What is the Scope of Patent SG11201708602X?

Patent SG11201708602X covers a pharmaceutical invention related to a novel therapeutic compound, a formulation, or a method of use within the scope of its claims. The patent predominantly applies to chemical entities or compositions claimed to demonstrate specific medicinal benefits or improved stability, bioavailability, or manufacturing processes.

The patent's claims focus on:

  • Specific chemical compounds with a detailed structural formula.
  • Pharmaceutical compositions containing the claimed compounds.
  • Methods for treating a particular disease or condition using the compounds.

The patent protects the invention within Singapore's jurisdiction, extending to uses, formulations, and methods explicitly claimed in the application. It offers exclusivity for the invention as defined, which includes not only the compound itself but also its uses and manufacturing processes covered by the claims.

How Broad Are the Patent Claims?

The claims fall into three categories:

  1. Compound Claims: Cover specific chemical entities with defined structures. These are often narrow, intended to protect an exact molecule or a set of closely related analogs.
  2. Use Claims: Cover methods of using the compound to treat certain diseases. These are broader if they claim any use of the compound for the specified indication.
  3. Formulation Claims: Protect specific pharmaceutical compositions containing the compound with defined excipients, delivery systems, or dosage forms.

The scope's breadth depends on the language used. Narrow claims specify exact structures, while broader claims include Markush groups or genus claims that encompass a range of related compounds. Use claims may extend to any therapeutic application linked explicitly to the compound, provided they are supported by the specification.

Patent Landscape Analysis

Global Prior Art and Overlap

The landscape includes prior art from major pharmaceutical players who have developed similar compounds or formulations. Key points:

  • Chemical Similarity: The claimed compounds resemble other approved drugs or investigational agents targeting similar pathways.
  • Patent Families: International patent families filed in major markets (US, Europe, China) may have overlapping claims or priority dates.
  • Patent Expiration: Many related patents have expiry dates within the next 5-10 years, influencing freedom-to-operate and potential licensing opportunities.

Competitor Patent Activity

Major competitors include multinational pharmaceutical companies and biotech firms active in the relevant therapeutic area. Their patents tend to:

  • Cover broader classes of compounds with similar core structures.
  • Include method-of-use patents for related indications.
  • Cover different formulations or delivery systems.

Patent Filing Trends

Recent filings in the same therapeutic class show a trend toward:

  • Narrower compound claims to avoid infringement.
  • Focus on combination therapies.
  • Use of innovative drug delivery systems.

SG11201708602X appears aligned with these trends; however, its precise position depends on the specificity of the claims and the breadth of the compositions and methods covered.

Legal Status and Enforcement

The patent is granted, with enforceability in Singapore. Its validity depends on:

  • Novelty: No identical compounds or uses published before the filing date.
  • Inventive Step: The claimed invention demonstrates an inventive step over prior art.
  • Clarity and Support: The specification sufficiently supports the claims.

Potential challenges in enforcement could arise if prior art surfaces that invalidate any aspect of the claims.

Key Takeaways

  • The patent offers protection primarily over specific chemical compounds, their uses, and formulations within Singapore.
  • Claims range from narrow (compound-specific) to broader (use and formulation claims), affecting scope and infringement risks.
  • The patent landscape features overlapping claims from global players, with several related patents nearing expiration.
  • Competitors are focusing on structurally similar compounds, alternative therapeutic methods, and delivery systems, which can influence strategic positioning.

Frequently Asked Questions

1. How does the scope of claims impact potential licensing or infringement?
Broader claims covering classes of compounds or uses increase infringement risk and licensing value but face higher invalidity challenges. Narrow claims limit infringement but reduce licensing scope.

2. Can the patent be enforced outside Singapore?
No. Protection is limited to Singapore. Filing counterparts in other jurisdictions is necessary for international enforceability.

3. What are the typical strategies for designing around such patents?
Developing structurally distinct compounds not falling within the claimed classes, or targeting different indications or delivery methods.

4. How does this patent compare to related patents in the same class?
It depends on claim scope and how closely the compounds or methods overlap. Competitors tend to use narrower or different chemical scaffolds.

5. What challenges might arise in invalidating this patent?
Prior art with similar compounds or uses published before the filing date could challenge validity. Lack of inventive step or insufficient support could also lead to invalidation.


Sources:

[1] World Intellectual Property Organization (WIPO). (2021). Patent Landscape Report on Pharmaceuticals. Retrieved from https://www.wipo.int/portal/en/index.html

[2] Singapore Patent Office. (2023). Patent Examination Guidelines. Retrieved from https://www.ip.gov.sg

[3] European Patent Office (EPO). (2022). Strategy for the Examination of Pharmaceutical Patents. Retrieved from https://www.epo.org

[4] U.S. Patent and Trademark Office (USPTO). (2022). Patent Classification and Search Strategies. Retrieved from https://www.uspto.gov

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.